Search

Background: Malaria is a life-threatening infectious disease of widespread burden. Malaria remains a leading communicable disease in the developing countries of the world. It occurs mostly in the tropical and subtropical regions and accounts for considerable morbidity and death. Malaria which is liable for a major amount of mortalities in endemic countries has been revealed to have both direct and indirect impacts on the haematologicalparameters.The study was done to compare the levels of haematological parameters of asymptomatic malaria patients based on age groups. Methods: The study is a cross-sectional study among asymptomatic malaria patients based on age groups. This study was conducted in Oda Road area of Akure, Ondo State. Two hundred (200) subjects were recruited for this study with each group comprising of 100 subjects for patients with asymptomatic malaria for the 2 age groups (16-30 years and 31-65 years). The data were presented in tables and as mean ± standard deviation and analyzed using student-test for parametric data and chi-square for non parametric data by statistical packages for social sciences (SPSS, Version 20.0) and level of significance set at as p≤ 0.05. Results: The results showed that subjects on age group 16-30 years were 100(50%) comprising of 50 males (25%) and 50 females (25). Also age group 31-65 years has 100 subjects (50%) comprising of 50 males (25%) and 50 females (25).The results showed significant difference in MCV (p=0.008), MCH (p=0.024) and no significant difference in PCV (p=0.675), WBC (p= 0.224), LYM (p=0.109), GRAN (p=0.061), MID (p=0.066), RBC (p=0.119), Hb (p=0.546), MCHC (p=0.262), PLT (p=0.783), when compared between age groups in years (16-30 and 31-65). Conclusion: The study showed increase in MCV and MCH of asymptomatic malaria patients within the age group of 31-65 years compared to asymptomatic malaria patients on 16-30 years age group. This shows that microcytic hypochromic anaemia may be experienced in asymptomatic malaria patients within the age group of 16-30 years more than in 31-65 years age group.

Recipients' immune systems are triggered by blood and blood component therapy. Transfusion-related immunomodulation (TRIM) is a complicated immunological response to transfusion that results in immunosuppression. The mechanisms of TRIM include the presence of residual white blood cells and apoptotic cells, the infusion of immunosuppressive cytokines that are present in donor components or that occur during blood processing, the transfer of metabolically active growth factor-loaded particles and extracellular vesicles, and the presence of hemoglobin or extracellular vesicles binds to hemoglobin. TRIM variables include donor-specific factors and processing variables. TRIM can explain, at least partially, the controversial negative clinical results observed in patients with covid19. Many potential treatment methods have been used in clinical practice, including supportive interventions, immunomodulators, antiviral therapy, and infusion of convalescent plasma. Here, we summarize current potential treatments for COVID-19 infection-related diseases and discuss the clinical value of blood transfusion-related technologies for COVID-19 treatment in blood transfusion-related immune regulation.

Severe Acute Respiratory Syndrome Coronavirus 2 is a new type of coronavirus that can cause Coronavirus Disease 2019 (Covid-19) and is associated with an increased risk of thrombosis-related pulmonary embolism. Globally, doctors have revised their management strategies for suspected and confirmed PD in patients with Coronavirus disease (Covid-19) in 2019. Choosing the right drug and the right dose requires consideration of potential comorbidities, which can be explained by the direct and indirect pathological consequences of Covid-19, complement activation, cytokine release, endothelial dysfunction, and the interaction between different types of blood cells. Discuss the pathophysiological events, therapeutic mortality strategies, risk factors and clinical management of patients with Covid-19 pulmonary embolism.